Clinicopathological and molecular features of claudin-18 isoform 2 expression in patients with colorectal cancer: a single-center retrospective study

Claudin-18 isoform 2 (CLDN18.2) is expressed in multiple cancers and is a promising target for antitumor therapy. However, there is limited knowledge regarding the prevalence and characteristics of CLDN18.2-positive colorectal cancer (CRC). To determine the clinicopathological and molecular features...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic advances in medical oncology 2024, Vol.16, p.17588359241286774
Main Authors: Takamizawa, Shigemasa, Hirano, Hidekazu, Takashima, Atsuo, Shoji, Hirokazu, Hirose, Toshiharu, Okita, Natsuko, Shiraishi, Kouya, Sekine, Shigeki, Takamizawa, Yasuyuki, Kanemitsu, Yukihide, Kato, Ken
Format: Article
Language:English
Subjects:
Original Research
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Claudin-18 isoform 2 (CLDN18.2) is expressed in multiple cancers and is a promising target for antitumor therapy. However, there is limited knowledge regarding the prevalence and characteristics of CLDN18.2-positive colorectal cancer (CRC). To determine the clinicopathological and molecular features of patients with CLDN18.2-positive CRC. Single-center retrospective study. A total of 805 patients who underwent surgical resection for pathological stage I III CRC at the National Cancer Center Hospital (Tokyo, Japan) between 1997 and 2019 were identified. Expression of CLDN18.2 was evaluated by immunohistochemistry. The association of CLDN18.2 expression with clinicopathological features and treatment outcomes was assessed. The cutoff for CLDN18.2 positivity was defined as ⩾1%. Among these patients, 17 (2.1%) had CLDN18.2-positive CRC. Right-sided CRC was significantly more common in patients who were CLDN18.2 positive than in those who were CLDN18.2 negative (76.5% vs 28.3%,  
ISSN:1758-8340
1758-8359
DOI:10.1177/17588359241286774